subfoveal

subfoveal

(sŭb-fō′vē-ăl) [″ + ″]
Beneath the fovea of the eye, that is, beneath the central portion of the macula.
References in periodicals archive ?
announced today the first patient has been enrolled in the multicenter Phase 2 clinical trial of NT-503 Encapsulated Cell Therapy (ECT) for the long-term treatment of recurrent subfoveal choroidal neovascularization secondary to age related macular degeneration (wet AMD).
It was initially approved by the FDA in April 2000 for the treatment of patients with predominantly classical subfoveal CNV due to AMD.
The trial is designed to assess the safety and tolerability of topical ocular PAN-90806 at three dosage strengths in patients with active, subfoveal choroidal neovascularization associated with neovascular AMD.
Liposomal amphotericin B was substituted for prophylactic anidulafungin, and an intravitreal injection of amphotericin B was given for a subfoveal lesion.
Verteporfin Therapy of Subfoveal Choroidal Neovascularization in Age-Related Macular Degeneration: Two-Year Results of a Randomized Clinical Trial Including Lesions with Occult with No Classic Choroidal Neovascularization-Verteporfin in Photodynamic Therapy Report 2.
Surgery for subfoveal choroidal neovascularization in age-related macular degeneration: Ophthalmic findings: SST report no.
This could be due to recent evidence that extensive intraosseous anastomoses exist between the superior retinacular arteries, the inferior vincular artery, and the subfoveal plexus.
Those suffers must have a particular type called predominantly classic subfoveal choroidal neovascularisation (CNV), it said.
Responsiveness of the National Eye Institute Visual Function Questionnaire to changes in visual acuity: Findings in patients with subfoveal choroidal neovascularization--SST Report No.
Nasdaq: QLTI; Toronto) has announced that the FDA has approved Visudyne(TM) (verteporfin for injection) therapy for the treatment of predominantly classic subfoveal choroidal neovascularization (CNV) due to pathologic myopia (severe near-sightedness) and presumed ocular histoplasmosis.
The intervention was a minimally invasive retrobulbar episcleral brachytherapy application (24 Gy as a single fraction) to the subfoveal neovascular membrane using a Sr-90 source.
Food and Drug Administration (FDA) has accepted and communicated Neurotech's ability to proceed with its Investigational New Drug (IND) application to conduct a Phase 2 clinical study of NT-503 Encapsulated Cell Therapy (ECT) for the treatment of recurrent subfoveal choroidal neovascularization secondary to age related macular degeneration (wet AMD).